Chemical Property of CID 657376
Chemical Property:
- Appearance/Colour:white crystalline powder
- Vapor Pressure:1.5E-06mmHg at 25°C
- Melting Point:196-197 °C
- Boiling Point:398.2 °C at 760 mmHg
- PKA:9.4(at 25℃)
- Flash Point:174 °C
- PSA：3.24000
- Density:1.076g/cm3
- LogP:4.97060
- Storage Temp.:2-8°C
- Solubility.:H2O: soluble
- Water Solubility.:almost transparency
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:2
- Rotatable Bond Count:3
- Exact Mass:313.1597275
- Heavy Atom Count:22
- Complexity:331
- Purity/Quality:
-
99%, *data from raw suppliers
Amitriptyline hydrochloride *data from reagent suppliers
Safty Information:
- Pictogram(s):
T, 
F
- Hazard Codes:T,F,N,Xn
- Statements:
23/24/25-36/37/38-42/43-63-39/23/24/25-11-50/53-36-22
- Safety Statements:
22-26-36/37/39-45-36/37-16-61-60-7
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Canonical SMILES:[H+].CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.[Cl-]
-
Description
Amitriptyline (hydrochloride) (CRM) (Item No. 19031) is a certified reference material categorized as a tricyclic antidepressant. This product is intended for analytical forensic applications. This product is also available as a general research tool .
-
Uses
Amitriptyline hydrochloride is a tricyclic antidepressant drug. Amitriptyline hydrochloride inhibits the norepinephrine and serotonin transporters but has a high affinity for α1-adrenergic, serotonin and muscarinic acetylcholine receptors. Amitriptyline hydrochloride has been used:as an antidepressant to study its effects on social behavior and memory in transgenic for acid sphingomyelinase (t-ASM) miceas a tricyclic antidepressant to analyze its effects on glucocorticoid receptor function in whole human bloodas an anti-depressant to study its effects on scratching and locomotion behavior in chloroquine-induced mouse
-
Therapeutic Function
Antidepressant
-
Clinical Use
Tricyclic antidepressant:
Depression, used especially where sedation is
required
Neuropathic pain (unlicensed)
Migraine prophylaxis (unlicensed)
-
Drug interactions
Potentially hazardous interactions with other drugs
Alcohol: increased sedative effect.
Analgesics: increased risk of CNS toxicity with
tramadol; possibly increased risk of side effects with
nefopam; possibly increased sedative effects with
opioids.
Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone - avoid; increased
risk of ventricular arrhythmias with disopyramide,
flecainide or propafenone; avoid with dronedarone.
Antibacterials: increased risk of ventricular
arrhythmias with moxifloxacin and delamanid -
avoid with moxifloxacin.
Anticoagulants: may alter anticoagulant effect of
coumarins.
Antidepressants: possibly increased serotonergic
effects with duloxetine; enhanced CNS excitation
and hypertension with MAOIs and moclobemide;
concentration possibly increased with SSRIs; risk
of ventricular arrhythmias with citalopram and
escitalopram - avoid; possible increased risk of
convulsions with vortioxetine; concentration reduced
by St John’s wort.
Antiepileptics: convulsive threshold lowered;
concentration reduced by carbamazepine,
phenobarbital and possibly fosphenytoin, phenytoin
and primidone.
Antimalarials: avoid with artemether/lumefantrine
and piperaquine with artenimol.
Antipsychotics: increased risk of ventricular
arrhythmias especially with droperidol, fluphenazine,
haloperidol, pimozide, sulpiride and zuclopenthixol
- avoid; increased antimuscarinic effects with
clozapine and phenothiazines; concentration
increased by antipsychotics.
Antivirals: increased risk of ventricular arrhythmias
with saquinavir - avoid; concentration possibly
increased with ritonavir.
Atomoxetine: increased risk of ventricular
arrhythmias and possibly convulsions.
Beta-blockers: increased risk of ventricular
arrhythmias with sotalol.
Clonidine: tricyclics antagonise hypotensive
effect; increased risk of hypertension on clonidine
withdrawal.
Cytotoxics: increased risk of ventricular arrhythmias
with arsenic trioxide.
Dapoxetine: possibly increased risk of serotonergic
effects - avoid. Dopaminergics: avoid with entacapone; CNS
toxicity reported with selegiline and rasagiline.
Pentamidine: increased risk of ventricular
arrhythmias.
Sympathomimetics: increased risk of hypertension
and arrhythmias with adrenaline and noradrenaline;
metabolism possibly inhibited by methylphenidate.
